PCI Biotech Holding ASA (OSL:PCIB) Debt-to-EBITDA : -0.01 (As of Jun. 2025)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

PCI Biotech Holding ASA OSL:PCIB

What is PCI Biotech Holding ASA Debt-to-EBITDA?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Debt-to-EBITDA is -0.01 as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Debt-to-EBITDA measures a company's ability to pay off its debt.

PCI Biotech Holding ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was kr0.28 Mil. PCI Biotech Holding ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was kr0.00 Mil. PCI Biotech Holding ASA's annualized EBITDA for the quarter that ended in Jun. 2025 was kr-22.29 Mil. PCI Biotech Holding ASA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2025 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PCI Biotech Holding ASA's Debt-to-EBITDA or its related term are showing as below:

OSL:PCIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.02 Med: -0.02 Max: -0.01
Current: -0.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of PCI Biotech Holding ASA was -0.01. The lowest was -0.02. And the median was -0.02.

OSL:PCIB's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.14 vs OSL:PCIB: -0.01

PCI Biotech Holding ASA (OSL:PCIB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PCI Biotech Holding ASA Debt-to-EBITDA Related Terms

PCI Biotech Holding ASA Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Debt-to-EBITDA Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.01

-0.02

PCI Biotech Holding ASA Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.03	-0.02	-0.03	-0.02	-0.01

OSL:PCIB vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Debt-to-EBITDA falls into.

Save Embed

6GF Score

PCI Biotech Holding ASA OSL:PCIB

Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PCI Biotech Holding ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PCI Biotech Holding ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.336	+	0)	/	-16.055
	=	-0.02

PCI Biotech Holding ASA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.282	+	0)	/	-22.292
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -0.01 mean?

PCI Biotech Holding ASA (OSL:PCIB) has a Debt-to-EBITDA of -0.01 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PCI Biotech Holding ASA.

Is PCI Biotech Holding ASA's Debt-to-EBITDA too high?

PCI Biotech Holding ASA's current Debt-to-EBITDA is -0.01. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.

How does PCI Biotech Holding ASA's Debt-to-EBITDA compare to VRTX and REGN?

PCI Biotech Holding ASA's Debt-to-EBITDA of -0.01 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Biotechnology company?

The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PCI Biotech Holding ASA. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current Debt-to-EBITDA is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PCI Biotech Holding ASA stock overvalued right now?

PCI Biotech Holding ASA (OSL:PCIB) has a current Debt-to-EBITDA of -0.01. The current Debt-to-EBITDA is -0.01. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Debt-to-EBITDA is -0.01 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Industry Healthcare Biotechnology

Comparable Companies VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM RVMD BNTX RPRX MRNA ROIV HKSE:01801 INCY HKSE:02269 SMMT OCSE:GMAB

Address Ullernchausseen 64, Oslo, NOR, N-0379

Website https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

6GF Score

Get the complete analysis for OSL:PCIB

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12

Price

View OSL:PCIB Analysis

See Debt-to-EBITDA data for all stocks →